Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
GWAS significance thresholds for deep phenotyping studies can depend upon minor allele frequencies and sample size.

Molecular psychiatry

Asif H, Alliey-Rodriguez N, Keedy S, Tamminga CA, Sweeney JA, Pearlson G, Clementz BA, Keshavan MS, Buckley P, Liu C, Neale B, Gershon ES.
PMID: 32066829
Mol Psychiatry. 2021 Jun;26(6):2048-2055. doi: 10.1038/s41380-020-0670-3. Epub 2020 Feb 17.

An important issue affecting genome-wide association studies with deep phenotyping (multiple correlated phenotypes) is determining the suitable family-wise significance threshold. Straightforward family-wise correction (Bonferroni) of p 

Cite
Asif H, Alliey-Rodriguez N, Keedy S, et al. GWAS significance thresholds for deep phenotyping studies can depend upon minor allele frequencies and sample size. Mol Psychiatry. 2020;26(6):2048-2055doi: 10.1038/s41380-020-0670-3.
Asif, H., Alliey-Rodriguez, N., Keedy, S., Tamminga, C. A., Sweeney, J. A., Pearlson, G., Clementz, B. A., Keshavan, M. S., Buckley, P., Liu, C., Neale, B., & Gershon, E. S. (2021). GWAS significance thresholds for deep phenotyping studies can depend upon minor allele frequencies and sample size. Molecular psychiatry, 26(6), 2048-2055. https://doi.org/10.1038/s41380-020-0670-3
Asif, Huma, et al. "GWAS significance thresholds for deep phenotyping studies can depend upon minor allele frequencies and sample size." Molecular psychiatry vol. 26,6 (2021): 2048-2055. doi: https://doi.org/10.1038/s41380-020-0670-3
Asif H, Alliey-Rodriguez N, Keedy S, Tamminga CA, Sweeney JA, Pearlson G, Clementz BA, Keshavan MS, Buckley P, Liu C, Neale B, Gershon ES. GWAS significance thresholds for deep phenotyping studies can depend upon minor allele frequencies and sample size. Mol Psychiatry. 2021 Jun;26(6):2048-2055. doi: 10.1038/s41380-020-0670-3. Epub 2020 Feb 17. PMID: 32066829; PMCID: PMC7429341.
Copy Download .nbib Format: NLM
Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders.

Progress in neuro-psychopharmacology & biological psychiatry

Zhang L, Hill SK, Guo B, Wu B, Alliey-Rodriguez N, Eum S, Lizano P, Ivleva EI, Reilly JL, Keefe RSE, Keedy SK, Tamminga CA, Pearlson GD, Clementz BA, Keshavan MS, Gershon ES, Sweeney JA, Bishop JR.
PMID: 34756932
Prog Neuropsychopharmacol Biol Psychiatry. 2022 Mar 08;113:110464. doi: 10.1016/j.pnpbp.2021.110464. Epub 2021 Oct 29.

BACKGROUND: Cognitive impairment is a core deficit across psychotic disorders, the causes and therapeutics of which remain unclear. Epidemiological observations have suggested associations between cognitive dysfunction in psychotic disorders and cardiovascular risk factors, but an underlying etiology has not...

Cite
Zhang L, Hill SK, Guo B, et al. Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2021;113:110464doi: 10.1016/j.pnpbp.2021.110464.
Zhang, L., Hill, S. K., Guo, B., Wu, B., Alliey-Rodriguez, N., Eum, S., Lizano, P., Ivleva, E. I., Reilly, J. L., Keefe, R. S. E., Keedy, S. K., Tamminga, C. A., Pearlson, G. D., Clementz, B. A., Keshavan, M. S., Gershon, E. S., Sweeney, J. A., & Bishop, J. R. (2022). Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Progress in neuro-psychopharmacology & biological psychiatry, 113110464. https://doi.org/10.1016/j.pnpbp.2021.110464
Zhang, Lusi, et al. "Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders." Progress in neuro-psychopharmacology & biological psychiatry vol. 113 (2022): 110464. doi: https://doi.org/10.1016/j.pnpbp.2021.110464
Zhang L, Hill SK, Guo B, Wu B, Alliey-Rodriguez N, Eum S, Lizano P, Ivleva EI, Reilly JL, Keefe RSE, Keedy SK, Tamminga CA, Pearlson GD, Clementz BA, Keshavan MS, Gershon ES, Sweeney JA, Bishop JR. Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Mar 08;113:110464. doi: 10.1016/j.pnpbp.2021.110464. Epub 2021 Oct 29. PMID: 34756932.
Copy Download .nbib Format: NLM
Publisher Correction: Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer.

Scientific reports

Ngô HM, Zhou Y, Lorenzi H, Wang K, Kim TK, Zhou Y, El Bissati K, Mui E, Fraczek L, Rajagopala SV, Roberts CW, Henriquez FL, Montpetit A, Blackwell JM, Jamieson SE, Wheeler K, Begeman IJ, Naranjo-Galvis C, Alliey-Rodriguez N, Davis RG, Soroceanu L, Cobbs C, Steindler DA, Boyer K, Noble AG, Swisher CN, Heydemann PT, Rabiah P, Withers S, Soteropoulos P, Hood L, McLeod R.
PMID: 31133744
Sci Rep. 2019 May 28;9(1):8110. doi: 10.1038/s41598-019-44545-0.

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

Cite
Ngô HM, Zhou Y, Lorenzi H, et al. Publisher Correction: Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Sci Rep. 2019;9(1):8110doi: 10.1038/s41598-019-44545-0.
Ngô, H. M., Zhou, Y., Lorenzi, H., Wang, K., Kim, T. K., Zhou, Y., El Bissati, K., Mui, E., Fraczek, L., Rajagopala, S. V., Roberts, C. W., Henriquez, F. L., Montpetit, A., Blackwell, J. M., Jamieson, S. E., Wheeler, K., Begeman, I. J., Naranjo-Galvis, C., Alliey-Rodriguez, N., Davis, R. G., Soroceanu, L., Cobbs, C., Steindler, D. A., Boyer, K., Noble, A. G., Swisher, C. N., Heydemann, P. T., Rabiah, P., Withers, S., Soteropoulos, P., Hood, L., & McLeod, R. (2019). Publisher Correction: Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Scientific reports, 9(1), 8110. https://doi.org/10.1038/s41598-019-44545-0
Ngô, Huân M, et al. "Publisher Correction: Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer." Scientific reports vol. 9,1 (2019): 8110. doi: https://doi.org/10.1038/s41598-019-44545-0
Ngô HM, Zhou Y, Lorenzi H, Wang K, Kim TK, Zhou Y, El Bissati K, Mui E, Fraczek L, Rajagopala SV, Roberts CW, Henriquez FL, Montpetit A, Blackwell JM, Jamieson SE, Wheeler K, Begeman IJ, Naranjo-Galvis C, Alliey-Rodriguez N, Davis RG, Soroceanu L, Cobbs C, Steindler DA, Boyer K, Noble AG, Swisher CN, Heydemann PT, Rabiah P, Withers S, Soteropoulos P, Hood L, McLeod R. Publisher Correction: Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Sci Rep. 2019 May 28;9(1):8110. doi: 10.1038/s41598-019-44545-0. PMID: 31133744; PMCID: PMC6536492.
Copy Download .nbib Format: NLM
Absence of coding somatic single nucleotide variants within well-known candidate genes in late-onset sporadic Alzheimer's Disease based on the analysis of multi-omics data.

Neurobiology of aging

Min S, Li Z, Shieh A, Giase G, Bao R, Zhang C, Kuney L, Kopp R, Asif H, Alliey-Rodriguez N, Qin L, Craig DW, Faulkner GJ, Gershon ES, Tang B, Chen C, Liu C.
PMID: 34392980
Neurobiol Aging. 2021 Dec;108:207-209. doi: 10.1016/j.neurobiolaging.2021.07.010. Epub 2021 Jul 21.

Somatic mutations arise randomly or are induced by environmental factors, which may increase the risk of Alzheimer's disease (AD). Identifying somatic mutations in sporadic AD (SAD) may provide new insight of the disease. To evaluate the potential contribution of...

Cite
Min S, Li Z, Shieh A, et al. Absence of coding somatic single nucleotide variants within well-known candidate genes in late-onset sporadic Alzheimer's Disease based on the analysis of multi-omics data. Neurobiol Aging. 2021;108:207-209doi: 10.1016/j.neurobiolaging.2021.07.010.
Min, S., Li, Z., Shieh, A., Giase, G., Bao, R., Zhang, C., Kuney, L., Kopp, R., Asif, H., Alliey-Rodriguez, N., Qin, L., Craig, D. W., Faulkner, G. J., Gershon, E. S., Tang, B., Chen, C., & Liu, C. (2021). Absence of coding somatic single nucleotide variants within well-known candidate genes in late-onset sporadic Alzheimer's Disease based on the analysis of multi-omics data. Neurobiology of aging, 108207-209. https://doi.org/10.1016/j.neurobiolaging.2021.07.010
Min, Shishi, et al. "Absence of coding somatic single nucleotide variants within well-known candidate genes in late-onset sporadic Alzheimer's Disease based on the analysis of multi-omics data." Neurobiology of aging vol. 108 (2021): 207-209. doi: https://doi.org/10.1016/j.neurobiolaging.2021.07.010
Min S, Li Z, Shieh A, Giase G, Bao R, Zhang C, Kuney L, Kopp R, Asif H, Alliey-Rodriguez N, Qin L, Craig DW, Faulkner GJ, Gershon ES, Tang B, Chen C, Liu C. Absence of coding somatic single nucleotide variants within well-known candidate genes in late-onset sporadic Alzheimer's Disease based on the analysis of multi-omics data. Neurobiol Aging. 2021 Dec;108:207-209. doi: 10.1016/j.neurobiolaging.2021.07.010. Epub 2021 Jul 21. PMID: 34392980.
Copy Download .nbib Format: NLM
Correction of depression-associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder.

Bipolar disorders

Federoff M, McCarthy MJ, Anand A, Berrettini WH, Bertram H, Bhattacharjee A, Calkin CV, Conroy C, Coryell WH, D'Arcangelo N, DeModena A, Fisher C, Feeder S, Frazier N, Frye MA, Gao K, Garnham J, Gershon ES, Alliey-Rodriguez N, Glazer K, Goes F, Karberg T, Harrington G, Jakobsen P, Kamali M, Kelly M, Leckband SG, Lohoff F, Maihofer AX, McInnis MG, Mondimore F, Morken G, Nurnberger JI, Oedegaard KJ, Ritchey M, Ryan K, Schinagle M, Schoeyen H, Schwebel C, Shaw M, Shilling PD, Slaney C, Stautland A, Tarwater B, Calabrese JR, Alda M, Nievergelt CM, Zandi PP, Kelsoe JR.
PMID: 34825444
Bipolar Disord. 2021 Nov 26; doi: 10.1111/bdi.13162. Epub 2021 Nov 26.

BACKGROUND: Bipolar disorder (BD) is characterized by episodes of depression and mania and disrupted circadian rhythms. Lithium is an effective therapy for BD, but only 30%-40% of patients are fully responsive. Preclinical models show that lithium alters circadian rhythms....

Cite
Federoff M, McCarthy MJ, Anand A, et al. Correction of depression-associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder. Bipolar Disord. 2021;doi: 10.1111/bdi.13162.
Federoff, M., McCarthy, M. J., Anand, A., Berrettini, W. H., Bertram, H., Bhattacharjee, A., Calkin, C. V., Conroy, C., Coryell, W. H., D'Arcangelo, N., DeModena, A., Fisher, C., Feeder, S., Frazier, N., Frye, M. A., Gao, K., Garnham, J., Gershon, E. S., Alliey-Rodriguez, N., Glazer, K., Goes, F., Karberg, T., Harrington, G., Jakobsen, P., Kamali, M., Kelly, M., Leckband, S. G., Lohoff, F., Maihofer, A. X., McInnis, M. G., Mondimore, F., Morken, G., Nurnberger, J. I., Oedegaard, K. J., Ritchey, M., Ryan, K., Schinagle, M., Schoeyen, H., Schwebel, C., Shaw, M., Shilling, P. D., Slaney, C., Stautland, A., Tarwater, B., Calabrese, J. R., Alda, M., Nievergelt, C. M., Zandi, P. P., & Kelsoe, J. R. (2021). Correction of depression-associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder. Bipolar disorders, . https://doi.org/10.1111/bdi.13162
Federoff, Monica, et al. "Correction of depression-associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder." Bipolar disorders vol. (2021). doi: https://doi.org/10.1111/bdi.13162
Federoff M, McCarthy MJ, Anand A, Berrettini WH, Bertram H, Bhattacharjee A, Calkin CV, Conroy C, Coryell WH, D'Arcangelo N, DeModena A, Fisher C, Feeder S, Frazier N, Frye MA, Gao K, Garnham J, Gershon ES, Alliey-Rodriguez N, Glazer K, Goes F, Karberg T, Harrington G, Jakobsen P, Kamali M, Kelly M, Leckband SG, Lohoff F, Maihofer AX, McInnis MG, Mondimore F, Morken G, Nurnberger JI, Oedegaard KJ, Ritchey M, Ryan K, Schinagle M, Schoeyen H, Schwebel C, Shaw M, Shilling PD, Slaney C, Stautland A, Tarwater B, Calabrese JR, Alda M, Nievergelt CM, Zandi PP, Kelsoe JR. Correction of depression-associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder. Bipolar Disord. 2021 Nov 26; doi: 10.1111/bdi.13162. Epub 2021 Nov 26. PMID: 34825444.
Copy Download .nbib Format: NLM
Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study.

Bipolar disorders

Lin Y, Maihofer AX, Stapp E, Ritchey M, Alliey-Rodriguez N, Anand A, Balaraman Y, Berrettini WH, Bertram H, Bhattacharjee A, Calkin CV, Conroy C, Coryell W, D'Arcangelo N, DeModena A, Biernacka JM, Fisher C, Frazier N, Frye M, Gao K, Garnham J, Gershon E, Glazer K, Goes FS, Goto T, Karberg E, Harrington G, Jakobsen P, Kamali M, Kelly M, Leckband SG, Lohoff FW, Stautland A, McCarthy MJ, McInnis MG, Mondimore F, Morken G, Nurnberger JI, Oedegaard KJ, Syrstad VEG, Ryan K, Schinagle M, Schoeyen H, Andreassen OA, Shaw M, Shilling PD, Slaney C, Tarwater B, Calabrese JR, Alda M, Nievergelt CM, Zandi PP, Kelsoe JR.
PMID: 33797828
Bipolar Disord. 2021 Apr 02; doi: 10.1111/bdi.13078. Epub 2021 Apr 02.

BACKGROUND: Lithium is regarded as a first-line treatment for bipolar disorder (BD), but partial response and non-response commonly occurs. There exists a need to identify lithium non-responders prior to initiating treatment. The Pharmacogenomics of Bipolar Disorder (PGBD) Study was...

Cite
Lin Y, Maihofer AX, Stapp E, et al. Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar Disord. 2021;doi: 10.1111/bdi.13078.
Lin, Y., Maihofer, A. X., Stapp, E., Ritchey, M., Alliey-Rodriguez, N., Anand, A., Balaraman, Y., Berrettini, W. H., Bertram, H., Bhattacharjee, A., Calkin, C. V., Conroy, C., Coryell, W., D'Arcangelo, N., DeModena, A., Biernacka, J. M., Fisher, C., Frazier, N., Frye, M., Gao, K., Garnham, J., Gershon, E., Glazer, K., Goes, F. S., Goto, T., Karberg, E., Harrington, G., Jakobsen, P., Kamali, M., Kelly, M., Leckband, S. G., Lohoff, F. W., Stautland, A., McCarthy, M. J., McInnis, M. G., Mondimore, F., Morken, G., Nurnberger, J. I., Oedegaard, K. J., Syrstad, V. E. G., Ryan, K., Schinagle, M., Schoeyen, H., Andreassen, O. A., Shaw, M., Shilling, P. D., Slaney, C., Tarwater, B., Calabrese, J. R., Alda, M., Nievergelt, C. M., Zandi, P. P., & Kelsoe, J. R. (2021). Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar disorders, . https://doi.org/10.1111/bdi.13078
Lin, Yian, et al. "Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study." Bipolar disorders vol. (2021). doi: https://doi.org/10.1111/bdi.13078
Lin Y, Maihofer AX, Stapp E, Ritchey M, Alliey-Rodriguez N, Anand A, Balaraman Y, Berrettini WH, Bertram H, Bhattacharjee A, Calkin CV, Conroy C, Coryell W, D'Arcangelo N, DeModena A, Biernacka JM, Fisher C, Frazier N, Frye M, Gao K, Garnham J, Gershon E, Glazer K, Goes FS, Goto T, Karberg E, Harrington G, Jakobsen P, Kamali M, Kelly M, Leckband SG, Lohoff FW, Stautland A, McCarthy MJ, McInnis MG, Mondimore F, Morken G, Nurnberger JI, Oedegaard KJ, Syrstad VEG, Ryan K, Schinagle M, Schoeyen H, Andreassen OA, Shaw M, Shilling PD, Slaney C, Tarwater B, Calabrese JR, Alda M, Nievergelt CM, Zandi PP, Kelsoe JR. Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar Disord. 2021 Apr 02; doi: 10.1111/bdi.13078. Epub 2021 Apr 02. PMID: 33797828.
Copy Download .nbib Format: NLM
Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders.

Progress in neuro-psychopharmacology & biological psychiatry

Zhang L, Hill SK, Guo B, Wu B, Alliey-Rodriguez N, Eum S, Lizano P, Ivleva EI, Reilly JL, Keefe RSE, Keedy SK, Tamminga CA, Pearlson GD, Clementz BA, Keshavan MS, Gershon ES, Sweeney JA, Bishop JR.
PMID: 34756932
Prog Neuropsychopharmacol Biol Psychiatry. 2022 Mar 08;113:110464. doi: 10.1016/j.pnpbp.2021.110464. Epub 2021 Oct 29.

BACKGROUND: Cognitive impairment is a core deficit across psychotic disorders, the causes and therapeutics of which remain unclear. Epidemiological observations have suggested associations between cognitive dysfunction in psychotic disorders and cardiovascular risk factors, but an underlying etiology has not...

Cite
Zhang L, Hill SK, Guo B, et al. Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2021;113:110464doi: 10.1016/j.pnpbp.2021.110464.
Zhang, L., Hill, S. K., Guo, B., Wu, B., Alliey-Rodriguez, N., Eum, S., Lizano, P., Ivleva, E. I., Reilly, J. L., Keefe, R. S. E., Keedy, S. K., Tamminga, C. A., Pearlson, G. D., Clementz, B. A., Keshavan, M. S., Gershon, E. S., Sweeney, J. A., & Bishop, J. R. (2022). Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Progress in neuro-psychopharmacology & biological psychiatry, 113110464. https://doi.org/10.1016/j.pnpbp.2021.110464
Zhang, Lusi, et al. "Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders." Progress in neuro-psychopharmacology & biological psychiatry vol. 113 (2022): 110464. doi: https://doi.org/10.1016/j.pnpbp.2021.110464
Zhang L, Hill SK, Guo B, Wu B, Alliey-Rodriguez N, Eum S, Lizano P, Ivleva EI, Reilly JL, Keefe RSE, Keedy SK, Tamminga CA, Pearlson GD, Clementz BA, Keshavan MS, Gershon ES, Sweeney JA, Bishop JR. Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Mar 08;113:110464. doi: 10.1016/j.pnpbp.2021.110464. Epub 2021 Oct 29. PMID: 34756932.
Copy Download .nbib Format: NLM
Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer.

Scientific reports

Ngô HM, Zhou Y, Lorenzi H, Wang K, Kim TK, Zhou Y, El Bissati K, Mui E, Fraczek L, Rajagopala SV, Roberts CW, Henriquez FL, Montpetit A, Blackwell JM, Jamieson SE, Wheeler K, Begeman IJ, Naranjo-Galvis C, Alliey-Rodriguez N, Davis RG, Soroceanu L, Cobbs C, Steindler DA, Boyer K, Noble AG, Swisher CN, Heydemann PT, Rabiah P, Withers S, Soteropoulos P, Hood L, McLeod R.
PMID: 28904337
Sci Rep. 2017 Sep 13;7(1):11496. doi: 10.1038/s41598-017-10675-6.

One third of humans are infected lifelong with the brain-dwelling, protozoan parasite, Toxoplasma gondii. Approximately fifteen million of these have congenital toxoplasmosis. Although neurobehavioral disease is associated with seropositivity, causality is unproven. To better understand what this parasite does...

Cite
Ngô HM, Zhou Y, Lorenzi H, et al. Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Sci Rep. 2017;7(1):11496doi: 10.1038/s41598-017-10675-6.
Ngô, H. M., Zhou, Y., Lorenzi, H., Wang, K., Kim, T. K., Zhou, Y., El Bissati, K., Mui, E., Fraczek, L., Rajagopala, S. V., Roberts, C. W., Henriquez, F. L., Montpetit, A., Blackwell, J. M., Jamieson, S. E., Wheeler, K., Begeman, I. J., Naranjo-Galvis, C., Alliey-Rodriguez, N., Davis, R. G., Soroceanu, L., Cobbs, C., Steindler, D. A., Boyer, K., Noble, A. G., Swisher, C. N., Heydemann, P. T., Rabiah, P., Withers, S., Soteropoulos, P., Hood, L., & McLeod, R. (2017). Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Scientific reports, 7(1), 11496. https://doi.org/10.1038/s41598-017-10675-6
Ngô, Huân M, et al. "Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer." Scientific reports vol. 7,1 (2017): 11496. doi: https://doi.org/10.1038/s41598-017-10675-6
Ngô HM, Zhou Y, Lorenzi H, Wang K, Kim TK, Zhou Y, El Bissati K, Mui E, Fraczek L, Rajagopala SV, Roberts CW, Henriquez FL, Montpetit A, Blackwell JM, Jamieson SE, Wheeler K, Begeman IJ, Naranjo-Galvis C, Alliey-Rodriguez N, Davis RG, Soroceanu L, Cobbs C, Steindler DA, Boyer K, Noble AG, Swisher CN, Heydemann PT, Rabiah P, Withers S, Soteropoulos P, Hood L, McLeod R. Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Sci Rep. 2017 Sep 13;7(1):11496. doi: 10.1038/s41598-017-10675-6. PMID: 28904337; PMCID: PMC5597608.
Copy Download .nbib Format: NLM
Detecting significant genotype-phenotype association rules in bipolar disorder: market research meets complex genetics.

International journal of bipolar disorders

Breuer R, Mattheisen M, Frank J, Krumm B, Treutlein J, Kassem L, Strohmaier J, Herms S, Mühleisen TW, Degenhardt F, Cichon S, Nöthen MM, Karypis G, Kelsoe J, Greenwood T, Nievergelt C, Shilling P, Shekhtman T, Edenberg H, Craig D, Szelinger S, Nurnberger J, Gershon E, Alliey-Rodriguez N, Zandi P, Goes F, Schork N, Smith E, Koller D, Zhang P, Badner J, Berrettini W, Bloss C, Byerley W, Coryell W, Foroud T, Guo Y, Hipolito M, Keating B, Lawson W, Liu C, Mahon P, McInnis M, Murray S, Nwulia E, Potash J, Rice J, Scheftner W, Zöllner S, McMahon FJ, Rietschel M, Schulze TG.
PMID: 30415424
Int J Bipolar Disord. 2018 Nov 11;6(1):24. doi: 10.1186/s40345-018-0132-x.

BACKGROUND: Disentangling the etiology of common, complex diseases is a major challenge in genetic research. For bipolar disorder (BD), several genome-wide association studies (GWAS) have been performed. Similar to other complex disorders, major breakthroughs in explaining the high heritability...

Cite
Breuer R, Mattheisen M, Frank J, et al. Detecting significant genotype-phenotype association rules in bipolar disorder: market research meets complex genetics. Int J Bipolar Disord. 2018;6(1):24doi: 10.1186/s40345-018-0132-x.
Breuer, R., Mattheisen, M., Frank, J., Krumm, B., Treutlein, J., Kassem, L., Strohmaier, J., Herms, S., Mühleisen, T. W., Degenhardt, F., Cichon, S., Nöthen, M. M., Karypis, G., Kelsoe, J., Greenwood, T., Nievergelt, C., Shilling, P., Shekhtman, T., Edenberg, H., Craig, D., Szelinger, S., Nurnberger, J., Gershon, E., Alliey-Rodriguez, N., Zandi, P., Goes, F., Schork, N., Smith, E., Koller, D., Zhang, P., Badner, J., Berrettini, W., Bloss, C., Byerley, W., Coryell, W., Foroud, T., Guo, Y., Hipolito, M., Keating, B., Lawson, W., Liu, C., Mahon, P., McInnis, M., Murray, S., Nwulia, E., Potash, J., Rice, J., Scheftner, W., Zöllner, S., McMahon, F. J., Rietschel, M., & Schulze, T. G. (2018). Detecting significant genotype-phenotype association rules in bipolar disorder: market research meets complex genetics. International journal of bipolar disorders, 6(1), 24. https://doi.org/10.1186/s40345-018-0132-x
Breuer, René, et al. "Detecting significant genotype-phenotype association rules in bipolar disorder: market research meets complex genetics." International journal of bipolar disorders vol. 6,1 (2018): 24. doi: https://doi.org/10.1186/s40345-018-0132-x
Breuer R, Mattheisen M, Frank J, Krumm B, Treutlein J, Kassem L, Strohmaier J, Herms S, Mühleisen TW, Degenhardt F, Cichon S, Nöthen MM, Karypis G, Kelsoe J, Greenwood T, Nievergelt C, Shilling P, Shekhtman T, Edenberg H, Craig D, Szelinger S, Nurnberger J, Gershon E, Alliey-Rodriguez N, Zandi P, Goes F, Schork N, Smith E, Koller D, Zhang P, Badner J, Berrettini W, Bloss C, Byerley W, Coryell W, Foroud T, Guo Y, Hipolito M, Keating B, Lawson W, Liu C, Mahon P, McInnis M, Murray S, Nwulia E, Potash J, Rice J, Scheftner W, Zöllner S, McMahon FJ, Rietschel M, Schulze TG. Detecting significant genotype-phenotype association rules in bipolar disorder: market research meets complex genetics. Int J Bipolar Disord. 2018 Nov 11;6(1):24. doi: 10.1186/s40345-018-0132-x. PMID: 30415424; PMCID: PMC6230336.
Copy Download .nbib Format: NLM
Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study.

Bipolar disorders

Lin Y, Maihofer AX, Stapp E, Ritchey M, Alliey-Rodriguez N, Anand A, Balaraman Y, Berrettini WH, Bertram H, Bhattacharjee A, Calkin CV, Conroy C, Coryell W, D'Arcangelo N, DeModena A, Biernacka JM, Fisher C, Frazier N, Frye M, Gao K, Garnham J, Gershon E, Glazer K, Goes FS, Goto T, Karberg E, Harrington G, Jakobsen P, Kamali M, Kelly M, Leckband SG, Lohoff FW, Stautland A, McCarthy MJ, McInnis MG, Mondimore F, Morken G, Nurnberger JI, Oedegaard KJ, Syrstad VEG, Ryan K, Schinagle M, Schoeyen H, Andreassen OA, Shaw M, Shilling PD, Slaney C, Tarwater B, Calabrese JR, Alda M, Nievergelt CM, Zandi PP, Kelsoe JR.
PMID: 33797828
Bipolar Disord. 2021 Dec;23(8):821-831. doi: 10.1111/bdi.13078. Epub 2021 May 05.

BACKGROUND: Lithium is regarded as a first-line treatment for bipolar disorder (BD), but partial response and non-response commonly occurs. There exists a need to identify lithium non-responders prior to initiating treatment. The Pharmacogenomics of Bipolar Disorder (PGBD) Study was...

Cite
Lin Y, Maihofer AX, Stapp E, et al. Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar Disord. 2021;23(8):821-831doi: 10.1111/bdi.13078.
Lin, Y., Maihofer, A. X., Stapp, E., Ritchey, M., Alliey-Rodriguez, N., Anand, A., Balaraman, Y., Berrettini, W. H., Bertram, H., Bhattacharjee, A., Calkin, C. V., Conroy, C., Coryell, W., D'Arcangelo, N., DeModena, A., Biernacka, J. M., Fisher, C., Frazier, N., Frye, M., Gao, K., Garnham, J., Gershon, E., Glazer, K., Goes, F. S., Goto, T., Karberg, E., Harrington, G., Jakobsen, P., Kamali, M., Kelly, M., Leckband, S. G., Lohoff, F. W., Stautland, A., McCarthy, M. J., McInnis, M. G., Mondimore, F., Morken, G., Nurnberger, J. I., Oedegaard, K. J., Syrstad, V. E. G., Ryan, K., Schinagle, M., Schoeyen, H., Andreassen, O. A., Shaw, M., Shilling, P. D., Slaney, C., Tarwater, B., Calabrese, J. R., Alda, M., Nievergelt, C. M., Zandi, P. P., & Kelsoe, J. R. (2021). Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar disorders, 23(8), 821-831. https://doi.org/10.1111/bdi.13078
Lin, Yian, et al. "Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study." Bipolar disorders vol. 23,8 (2021): 821-831. doi: https://doi.org/10.1111/bdi.13078
Lin Y, Maihofer AX, Stapp E, Ritchey M, Alliey-Rodriguez N, Anand A, Balaraman Y, Berrettini WH, Bertram H, Bhattacharjee A, Calkin CV, Conroy C, Coryell W, D'Arcangelo N, DeModena A, Biernacka JM, Fisher C, Frazier N, Frye M, Gao K, Garnham J, Gershon E, Glazer K, Goes FS, Goto T, Karberg E, Harrington G, Jakobsen P, Kamali M, Kelly M, Leckband SG, Lohoff FW, Stautland A, McCarthy MJ, McInnis MG, Mondimore F, Morken G, Nurnberger JI, Oedegaard KJ, Syrstad VEG, Ryan K, Schinagle M, Schoeyen H, Andreassen OA, Shaw M, Shilling PD, Slaney C, Tarwater B, Calabrese JR, Alda M, Nievergelt CM, Zandi PP, Kelsoe JR. Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar Disord. 2021 Dec;23(8):821-831. doi: 10.1111/bdi.13078. Epub 2021 May 05. PMID: 33797828.
Copy Download .nbib Format: NLM
Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study.

Bipolar disorders

Lin Y, Maihofer AX, Stapp E, Ritchey M, Alliey-Rodriguez N, Anand A, Balaraman Y, Berrettini WH, Bertram H, Bhattacharjee A, Calkin CV, Conroy C, Coryell W, D'Arcangelo N, DeModena A, Biernacka JM, Fisher C, Frazier N, Frye M, Gao K, Garnham J, Gershon E, Glazer K, Goes FS, Goto T, Karberg E, Harrington G, Jakobsen P, Kamali M, Kelly M, Leckband SG, Lohoff FW, Stautland A, McCarthy MJ, McInnis MG, Mondimore F, Morken G, Nurnberger JI, Oedegaard KJ, Syrstad VEG, Ryan K, Schinagle M, Schoeyen H, Andreassen OA, Shaw M, Shilling PD, Slaney C, Tarwater B, Calabrese JR, Alda M, Nievergelt CM, Zandi PP, Kelsoe JR.
PMID: 33797828
Bipolar Disord. 2021 Dec;23(8):821-831. doi: 10.1111/bdi.13078. Epub 2021 May 05.

BACKGROUND: Lithium is regarded as a first-line treatment for bipolar disorder (BD), but partial response and non-response commonly occurs. There exists a need to identify lithium non-responders prior to initiating treatment. The Pharmacogenomics of Bipolar Disorder (PGBD) Study was...

Cite
Lin Y, Maihofer AX, Stapp E, et al. Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar Disord. 2021;23(8):821-831doi: 10.1111/bdi.13078.
Lin, Y., Maihofer, A. X., Stapp, E., Ritchey, M., Alliey-Rodriguez, N., Anand, A., Balaraman, Y., Berrettini, W. H., Bertram, H., Bhattacharjee, A., Calkin, C. V., Conroy, C., Coryell, W., D'Arcangelo, N., DeModena, A., Biernacka, J. M., Fisher, C., Frazier, N., Frye, M., Gao, K., Garnham, J., Gershon, E., Glazer, K., Goes, F. S., Goto, T., Karberg, E., Harrington, G., Jakobsen, P., Kamali, M., Kelly, M., Leckband, S. G., Lohoff, F. W., Stautland, A., McCarthy, M. J., McInnis, M. G., Mondimore, F., Morken, G., Nurnberger, J. I., Oedegaard, K. J., Syrstad, V. E. G., Ryan, K., Schinagle, M., Schoeyen, H., Andreassen, O. A., Shaw, M., Shilling, P. D., Slaney, C., Tarwater, B., Calabrese, J. R., Alda, M., Nievergelt, C. M., Zandi, P. P., & Kelsoe, J. R. (2021). Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar disorders, 23(8), 821-831. https://doi.org/10.1111/bdi.13078
Lin, Yian, et al. "Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study." Bipolar disorders vol. 23,8 (2021): 821-831. doi: https://doi.org/10.1111/bdi.13078
Lin Y, Maihofer AX, Stapp E, Ritchey M, Alliey-Rodriguez N, Anand A, Balaraman Y, Berrettini WH, Bertram H, Bhattacharjee A, Calkin CV, Conroy C, Coryell W, D'Arcangelo N, DeModena A, Biernacka JM, Fisher C, Frazier N, Frye M, Gao K, Garnham J, Gershon E, Glazer K, Goes FS, Goto T, Karberg E, Harrington G, Jakobsen P, Kamali M, Kelly M, Leckband SG, Lohoff FW, Stautland A, McCarthy MJ, McInnis MG, Mondimore F, Morken G, Nurnberger JI, Oedegaard KJ, Syrstad VEG, Ryan K, Schinagle M, Schoeyen H, Andreassen OA, Shaw M, Shilling PD, Slaney C, Tarwater B, Calabrese JR, Alda M, Nievergelt CM, Zandi PP, Kelsoe JR. Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar Disord. 2021 Dec;23(8):821-831. doi: 10.1111/bdi.13078. Epub 2021 May 05. PMID: 33797828.
Copy Download .nbib Format: NLM
An opportunity for primary prevention research in psychotic disorders.

Schizophrenia research

Gershon ES, Lee SH, Zhou X, Sweeney JA, Tamminga C, Pearlson GA, Clementz BA, Keshavan MS, Alliey-Rodriguez N, Hudgens-Haney M, Keedy SK, Glahn DC, Asif H, Lencer R, Hill SK.
PMID: 34315649
Schizophr Res. 2021 Jul 24; doi: 10.1016/j.schres.2021.07.001. Epub 2021 Jul 24.

An opportunity has opened for research into primary prevention of psychotic disorders, based on progress in endophenotypes, genetics, and genomics. Primary prevention requires reliable prediction of susceptibility before any symptoms are present. We studied a battery of measures where...

Cite
Gershon ES, Lee SH, Zhou X, et al. An opportunity for primary prevention research in psychotic disorders. Schizophr Res. 2021;doi: 10.1016/j.schres.2021.07.001.
Gershon, E. S., Lee, S. H., Zhou, X., Sweeney, J. A., Tamminga, C., Pearlson, G. A., Clementz, B. A., Keshavan, M. S., Alliey-Rodriguez, N., Hudgens-Haney, M., Keedy, S. K., Glahn, D. C., Asif, H., Lencer, R., & Hill, S. K. (2021). An opportunity for primary prevention research in psychotic disorders. Schizophrenia research, . https://doi.org/10.1016/j.schres.2021.07.001
Gershon, Elliot S, et al. "An opportunity for primary prevention research in psychotic disorders." Schizophrenia research vol. (2021). doi: https://doi.org/10.1016/j.schres.2021.07.001
Gershon ES, Lee SH, Zhou X, Sweeney JA, Tamminga C, Pearlson GA, Clementz BA, Keshavan MS, Alliey-Rodriguez N, Hudgens-Haney M, Keedy SK, Glahn DC, Asif H, Lencer R, Hill SK. An opportunity for primary prevention research in psychotic disorders. Schizophr Res. 2021 Jul 24; doi: 10.1016/j.schres.2021.07.001. Epub 2021 Jul 24. PMID: 34315649.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries